Bank of America’s Citius Oncology CTOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.37M Buy
3,835,160
+3,834,946
+1,792,031% +$3.85M ﹤0.01% 3999
2025
Q4
$214 Sell
214
-50
-19% -$72 ﹤0.01% 6683
2025
Q3
$536 Sell
264
-8,307
-97% -$18K ﹤0.01% 7576
2025
Q2
$37.3K Buy
8,571
+8,411
+5,257% +$9.82K ﹤0.01% 6895
2025
Q1
$149 Hold
160
﹤0.01% 7757
2024
Q4
$184 Hold
160
﹤0.01% 7609
2024
Q3
$222 Buy
+160
New +$1.14K ﹤0.01% 7544

Other funds holding CTOR

Bank of America's CTOR Position: Q1 2026 in Review

Bank of America increased its Citius Oncology (CTOR) stake by 1,792,031% in Q1 2026, buying an estimated $3.85M and bringing the position to 3,835,160 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Bank of America first reported a position in CTOR in Q3 2024 and has held it in 7 quarters since. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • Bank of America held 3,835,160 shares of Citius Oncology worth $2.37M as of Q1 2026.
  • Bank of America bought 3,834,946 Citius Oncology shares in Q1 2026, an estimated $3.85M.
  • Citius Oncology made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3999 holding.
  • Bank of America first reported a position in Citius Oncology in Q3 2024 and has held it in 7 quarters since.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.